Over four years ago, in October 2014, Amgen initiated a patent infringement suit against Sanofi and Regeneron regarding biologics for...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Sanofi
-
-
On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Last week, Mylan N.V. and Biocon Ltd. announced that their jointly-developed insulin glargine biosimilar, Semglee™, received marketing...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. recently scored a victory in their ongoing dispute over a...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On December 20, 2017, Bristol Myers Squibb Company, Bavarian Nordic, and Enzo Biochem, Inc. filed an amicus brief in support of Amgen’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In October, a Federal Circuit panel vacated a permanent injunction against Sanofi and Regeneron’s Praluent® and remanded the proceeding...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On August 8, 2017, Sanofi-Aventis (“Sanofi”) filed a patent infringement suit in the United States District Court for the District of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Merck & Co., Inc. (“Merck”) announced last week that the FDA has granted tentative approval for its insulin glargine injection...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The battle over the proper forum for patent infringement litigation regarding Dupixent® (Dupilumab) appears to have been resolved. Last...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]